Studying fewer airway clearance treatments for children with cystic fibrosis
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study looks at whether doing airway clearance therapies less often can be just as effective as doing them every day for children and teens with cystic fibrosis who are taking a modulator medicine. The goal is to see if a simpler treatment schedule can keep lungs healthy while making daily life easier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Ages 3 to 16 years old (all genders)
- A confirmed diagnosis of cystic fibrosis
- Taking a CF medicine called a modulator (like Trikafta or a similar drug) for at least 3 months before the study starts and continuing it during the study
- Lung function of at least 70% of what is expected for your age (checked with a breathing test)
- Feeling stable - no major health changes or new treatments (such as antibiotics or steroids) in the 28 days before screening
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether people with cystic fibrosis who are already on a triple combination CFTR modulator can stay on their treatment without interruptions or problems. It aims to make sure everyone gets the best, most consistent treatment for their CF.
This study tests a fun mobile app designed to help children and teens with cystic fibrosis do their daily airway clearance exercises. If your child is between 8 and 20 years old and has CF, they might be able to join and possibly make breathing treatments more enjoyable.
This study tests a streamlined approach to managing sudden lung symptoms (pulmonary exacerbations) in children with cystic fibrosis. It aims to see if a simpler treatment plan works as well as standard care, which could mean less time in the hospital and fewer disruptions to daily life.
This Phase 2 trial tests 4D-710 to improve lung health in adults with cystic fibrosis who either cannot take CFTR modulator medicines or are not doing well enough on them. You may be eligible if you have moderate lung function and stable oxygen levels, and you meet other safety and health requirements.
This study tests new treatments for cystic fibrosis in people who cannot take or choose not to take current CFTR modulators. It aims to find better options for managing CF.
This study looks at how well a highly effective cystic fibrosis (CF) medicine works in infants and young children, and what biological changes it causes. It may help families understand whether the medicine improves CF function and related measures early in life.
Hear when a new Cystic Fibrosis (CF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.